Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 7/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504689 | 0.77 | FBP1 (1.00) | FBP1FFAR1PTGESALOX5HIF1A | |
| SCHEMBL31580496 | 0.77 | FFAR1 (1.00) | FBP1FFAR1PTGESALOX5BCL2L1 | |
| SCHEMBL7887580 | 0.74 | FFAR1 (0.85) | FBP1FFAR1PTGESALOX5BCL2L1 | |
| Isodispar B SCHEMBL29516983 | 0.73 | HIF1A (0.64) | FBP1FFAR1HIF1AEPAS1 | |
| SCHEMBL29287621 | 0.71 | FFAR1 (0.79) | FBP1FFAR1PTGESALOX5BCL2L1 | |
| SCHEMBL28843642 | 0.70 | FFAR1 (0.77) | FBP1FFAR1PTGESALOX5BCL2L1 | |
| SCHEMBL6276169 | 0.67 | FFAR1 (0.71) | FBP1FFAR1BCL2L1 | |
| Rhodomyrtoxin SCHEMBL12210330 | 0.66 | FBP1 (0.49) | FBP1FFAR1HIF1AEPAS1BCL2L1 | |
| SCHEMBL7221645 | 0.65 | ELANE (0.58) | FBP1FFAR1 | |
| SCHEMBL504402 | 0.65 | MEN1 (0.55) | FBP1FFAR1PTGESALOX5HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273021-B2 | Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273021-B2 | Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273021-B2 | Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2016-03-01 | — | — | US | disclosed |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010091185-A2 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091185-A2 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | FBP1, SLC5A1, ALDOA | FBP1 1/4885FFAR1 363/4885PTGES 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.